Clinicopathologic significance of combined hepatocellular- cholangiocarcinoma with stem cell subtype components with reference to the expression of putative stem cell markers

American Journal of Clinical Pathology

Volumn 140, Issue 3, 2013, Pages 329-340

  Ikeda, Hiroko ^a   Harada, Kenichi ^b   Sato, Yasunori ^b   Sasaki, Motoko ^b   Yoneda, Norihide ^a   Kitamura, Seiko ^a   Sudo, Yoshiko ^c   Ooi, Akishi ^b   Nakanuma, Yasuni ^a,b  

^a KANAZAWA UNIVERSITY HOSPITAL   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c FUKUI KEN SAISEIKAI HOSPITAL   (Japan)

Author keywords

Combined hepatocellular cholangiocarcinoma; DLK1; Hepatoblast; NCAM CD56; Stem cells

Indexed keywords

CD133 ANTIGEN; CD56 ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE; GLYPICAN 3;

ARTICLE; BILE DUCT CARCINOMA; CANCER CLASSIFICATION; CANCER STEM CELL; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DEVELOPMENT; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; WORLD HEALTH ORGANIZATION;

COMBINED HEPATOCELLULAR-CHOLANGIOCARCINOMA; DLK1; HEPATOBLAST; NCAM/CD56; STEM CELLS;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; FEMALE; GLYCOPROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEURAL CELL ADHESION MOLECULES; PEPTIDES; STEM CELLS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84882766248     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP66AVBANVNTQJ     Document Type: Article

References (21)

1. Theise ND, Park YN, Nakanuma Y. Combined hepatocellular- cholangiocarcinoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, eds. WHO Classification of Tumours of the Digestive System. 4th ed. Lyon, France: IARC; 2010:225-227.
2. Theise ND, Yao JL, Harada K, et al. Hepatic "stem cell" malignancies in adults: four cases. Histopathology. 2003;43:263-271.
3. Chiba T, Zheng YW, Kita K, et al. Enhanced self-renewal capability in hepatic stem/progenitor cells drives cancer initiation. Gastroenterology. 2007;13:937-950.
4. Zhang F, Chen XP, Zhang W, et al. Combined hepatocellular cholangiocarcinoma originating from hepatic progenitor cells: immunohistochemical and double-fluorescence immunostaining evidence. Histopathology. 2008;52:224-232.
5. Woo HG, Lee JH, Yoon JH, et al. Identification of a cholangiocarcinoma- like gene expression trait in hepatocellular carcinoma. Cancer Res. 2010;70:3034-3041.
6. Tanimizu N, Nishikawa M, Saito H, et al. Isolation of hepatoblasts based on the expression of Dlk/Pref-1. J Cell Sci. 2003;116:1775-1786.
7. Jensen CH, Jauho EI, Santoni-Rugiu E, et al. Transitamplifying ductular (oval) cells and their hepatocytic progeny are characterized by a novel and distinctive expression of delta-like protein/preadipocyte factor 1/fetal antigen 1. Am J Pathol. 2004;164:1347-1359.
8. Oertel M, Menthena A, Chen YQ, et al. Purification of fetal liver stem/progenitor cells containing all the repopulation potential for normal adult rat liver. Gastroenterology. 2008;134:823-832.
9. Floridon C, Jensen CH, Thorsen P, et al. Does fetal antigen 1 (FA1) identify cells with regenerative, endocrine and neuroendocrine potentials? a study of FA1 in embryonic, fetal, and placental tissue and in maternal circulation. Differentiation. 2000;66:49-59.
10. Yanai H, Nakamura K, Hijioka S, et al. Dlk-1, a cell surface antigen on foetal hepatic stem/progenitor cells, is expressed in hepatocellular, colon, pancreas and breast carcinomas at a high frequency. J Biochem. 2010;148:85-92.
11. Luo JH, Ren B, Keryanov S, et al. Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology. 2006;44:1012-1024.
12. Huang J, Zhang X, Zhang M, et al. Up-regulation of DLK1 as an imprinted gene could contribute to human hepatocellular carcinoma. Carcinogenesis. 2007;28:1094-1103.
13. Dezso K, Halász J, Bisgaard HC, et al. Delta-like protein (DLK) is a novel immunohistochemical marker for human hepatoblastomas. Virchows Arch. 2008;452:443-448.
14. Xu X, Liu RF, Zhang X, et al. DLK1 as a potential target against cancer stem/progenitor cells of hepatocellular carcinoma. Mol Cancer Ther. 2012;11:629-638.
15. Komuta M, Govaere O, Vandecaveye V, et al. Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes. Hepatology. 2012;55:1876-1888.
16. Fujii T, Zen Y, Harada K, et al. Participation of liver cancer stem/progenitor cells in tumorigenesis of scirrhous hepatocellular carcinoma-human and cell culture study. Hum Pathol. 2008;39:1185-1196.
17. Kozaka K, Sasaki M, Fujii T, et al. A subgroup of intrahepatic cholangiocarcinoma with an infiltrating replacement growth pattern and a resemblance to reactive proliferating bile ductules: 'bile ductular carcinoma'. Histopathology. 2007; 51:390-400.
18. Yoshikawa S, Zen Y, Fujii T, et al. Characterization of CD133+ parenchymal cells in the liver: histology and culture. World J Gastroenterol. 2009;15:4896-4906.
19. Komuta M, Spee B, Vander Borght S, et al. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology. 2008;47:1544-1556.
20. Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105-111.
21. Al-Hajj M, Clarke MF. Self-renewal and solid tumor stem cells. Oncogene. 2004;23:7274-7282.